Literature DB >> 19622837

Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Meenakshi Sundaram1, Shumei Zhong, Maroun Bou Khalil, Philip H Links, Yang Zhao, Jahangir Iqbal, M Mahmood Hussain, Robin J Parks, Yuwei Wang, Zemin Yao.   

Abstract

Apolipoprotein (apo) C-III plays a regulatory role in VLDL lipolysis and clearance. In this study, we determined a potential intracellular role of apoC-III in hepatic VLDL assembly and secretion. Stable expression of recombinant apoC-III in McA-RH7777 cells resulted in increased secretion efficiency of VLDL-associated triacylglycerol (TAG) and apoB-100 in a gene-dosage-dependent manner. The stimulatory effect of apoC-III on TAG secretion was manifested only when cells were cultured under lipid-rich (i.e., media supplemented with exogenous oleate) but not lipid-poor conditions. The stimulated TAG secretion was accompanied by increased secretion of apoB-100 and apoB-48 as VLDL(1). Expression of apoC-III also increased mRNA and activity of microsomal triglyceride transfer protein (MTP). Pulse-chase experiments showed that apoC-III expression promoted VLDL(1) secretion even under conditions where the MTP activity was inhibited immediately after the formation of lipid-poor apoB-100 particles, suggesting an involvement of apoC-III in the second-step VLDL assembly process. Consistent with this notion, the newly synthesized apoC-III was predominantly associated with TAG within the microsomal lumen that resembled lipid precursors of VLDL. Introducing an Ala23-to-Thr mutation into apoC-III, a naturally occurring mutation originally identified in two Mayan Indian subjects with hypotriglyceridemia, abolished the ability of apoC-III to stimulate VLDL secretion from transfected cells. Thus, expression of apoC-III in McA-RH7777 cells enhances hepatic TAG-rich VLDL assembly and secretion under lipid-rich conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19622837      PMCID: PMC2789775          DOI: 10.1194/M900346-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  42 in total

1.  Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.

Authors:  G Schonfeld; P K George; J Miller; P Reilly; J Witztum
Journal:  Metabolism       Date:  1979-10       Impact factor: 8.694

2.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  A simple and efficient procedure for the rapid homogenization of cultured animal cells grown in monolayer.

Authors:  T Y Chang; J S Limanek; C C Chang
Journal:  Anal Biochem       Date:  1981-09-15       Impact factor: 3.365

5.  Isolation and analysis of lipoproteins secreted by rat liver hepatocytes.

Authors:  D E Vance; D B Weinstein; D Steinberg
Journal:  Biochim Biophys Acta       Date:  1984-01-17

6.  DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis.

Authors:  S K Karathanasis; E Ferris; I A Haddad
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

7.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

8.  The level and compartmentalization of phosphatidate phosphatase-1 (lipin-1) control the assembly and secretion of hepatic VLDL.

Authors:  Maroun Bou Khalil; Meenakshi Sundaram; Hong-Yu Zhang; Philip H Links; Jennifer F Raven; Boripont Manmontri; Meltem Sariahmetoglu; Khai Tran; Karen Reue; David N Brindley; Zemin Yao
Journal:  J Lipid Res       Date:  2008-09-03       Impact factor: 5.922

9.  An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis.

Authors:  S K Karathanasis; R A Norum; V I Zannis; J L Breslow
Journal:  Nature       Date:  1983-02-24       Impact factor: 49.962

10.  Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Authors:  Jeffrey S Cohn; Bruce W Patterson; Kris D Uffelman; Jean Davignon; George Steiner
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  66 in total

Review 1.  Genetics of lipid traits and relationship to coronary artery disease.

Authors:  Tanya E Keenan; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

Review 2.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

3.  Secretion of triacylglycerol-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase.

Authors:  Michelle Bamji-Mirza; Meenakshi Sundaram; Shumei Zhong; Erik F Yao; Robin J Parks; Zemin Yao
Journal:  J Lipid Res       Date:  2010-12-27       Impact factor: 5.922

Review 4.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

5.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

6.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

7.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

8.  Key differences between apoC-III regulation and expression in intestine and liver.

Authors:  Gabrielle West; Cayla Rodia; Diana Li; Zania Johnson; Hongli Dong; Alison B Kohan
Journal:  Biochem Biophys Res Commun       Date:  2017-07-21       Impact factor: 3.575

9.  Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.

Authors:  Javeed Jattan; Cayla Rodia; Diana Li; Adama Diakhate; Hongli Dong; Amy Bataille; Noah F Shroyer; Alison B Kohan
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

10.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.